【2020-ASCO-NSCLC-口服-課件-幻燈】Discussion_Maximizing-benefits-of-EGFR-targeted-therapies

1、Maximizing the Benefits of (EGFR) Targeted TherapiesPresented By Rachel Sanborn at TBDMaximizing the Benefits of (EGFR) Targeted TherapiesPresented By Rachel Sanborn at TBDSlide 3Presented By Rachel Sanborn at TBDSlide 4Presented By Rachel Sanborn at TBDSlide 5Presented By Rachel Sanborn at TBDIs TK

2、I/VEGF Better Than TKI Alone?Presented By Rachel Sanborn at TBDIs TKI/VEGF Better Than TKI/Chemo?Presented By Rachel Sanborn at TBDSlide 8Presented By Rachel Sanborn at TBDNEJ026, Take Home PointsPresented By Rachel Sanborn at TBDOsimertinib +VEGF Inhibition?Presented By Rachel Sanborn at TBDMaximiz

3、ing the Benefits of (EGFR) Targeted TherapiesPresented By Rachel Sanborn at TBDConcurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC)Presented By Rachel Sanborn at TBDFeasibilityPresented By Rachel Sanborn at TBDRapid plasma clearance of EGF

4、R mutationsPresented By Rachel Sanborn at TBDOsimertinib + Gefitinib, ConsiderationsPresented By Rachel Sanborn at TBDOsimertinib + Gefitinib, Take Home PointsPresented By Rachel Sanborn at TBDMaximizing the Benefits of (EGFR) Targeted TherapiesPresented By Rachel Sanborn at TBDFirst-Line Tyrosine K

5、inase Inhibitor With or Without Aggressive Upfront Local Radiation Therapy In Patients With EGFRm Oligometastatic Non-Small-Cell Lung Cancer: Interim Results of A Randomized Phase III, Open-Label ClinicalTrial (SINDAS) (NCT02893332).Presented By Rachel Sanborn at TBDSINDAS: Participants Characterist

6、ics Presented By Rachel Sanborn at TBDKaplan-Meier plot of PFS (A) and OS (B)Presented By Rachel Sanborn at TBDToxicity（Grade 3 adverse events）Presented By Rachel Sanborn at TBDSlide 22Presented By Rachel Sanborn at TBDSINDAS Trial, Questions and Take Home PointsPresented By Rachel Sanborn at TBDSINDAS Trial, Take Home Points, 2Presented By Rachel Sanborn at TBDMaximizing the Benefits of (EGF